Fragment-based drug discovery in academia: Experiences from a tuberculosis programme

NATO Science for Peace and Security Series A: Chemistry and Biology

Volumn , Issue , 2009, Pages 21-36

  Heikkila, Timo J ^a   Surade, Sachin ^a   Silvestre, Hernani L ^a   Dias, Marcio V B ^a   Ciulli, Alessio ^a   Bromfield, Karen ^a   Scott, Duncan ^a   Howard, Nigel ^a   Wen, Shijun ^a   Wei, Alvin Hung ^a   Osborne, David ^a   Abell, Chris ^a   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Drug discovery; Fragment based; Resistance; Tuberculosis

Indexed keywords

MYCOBACTERIUM TUBERCULOSIS;

EID: 79952579786     PISSN: 18746489     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-2339-1_3     Document Type: Conference Paper

References (61)

1. Alex AA, Flocco MM. Fragment-based drug discovery: what has it achieved so far? Curr Top Med Chem. 2007;7(7):1544-67. (Pubitemid 350131014)
2. Barry CE 3rd, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, Yuan Y. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res. 1998;37(2-3): 143-79. (Pubitemid 28391410)
3. Bentley R. The shikimate pathway-a metabolic tree with many branches. Crit Rev Biochem Mol Biol. 1990;25(25):307-84. (Pubitemid 120012279)
4. Beste DJ, Hooper T, Stewart G, Bonde B, Avignone-Rossa C, Bushell ME, Wheeler P, Klamt S, Kierzek AM, McFadden J. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol. 2007;8(8):R89.
5. Blundell TL. Structure-based drug design. Nature. 1996;384(6604 Suppl): 23-6. (Pubitemid 26374536)
6. Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov. 2002;1(1):45-54. (Pubitemid 37361403)
7. Bosch J, Robien MA, Mehlin C, Boni E, Riechers A, Buckner FS, Van Voorhis WC, Myler PJ, Worthey EA, DeTitta G, Luft JR, Lauricella A, Gulde S, Anderson LA, Kalyuzhniy O, Neely HM, Ross J, Earnest TN, Soltis M, Schoenfeld L, Zucker F, Merritt EA, Fan E, Verlinde CL, Hol WG. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem. 2006;49(49):5939-46. (Pubitemid 44484940)
8. Caldwell JJ, Davies TG, Donald A, McHardy T, Rowlands MG, Aherne GW, Hunter LK, Taylor K, Ruddle R, Raynaud FI, Verdonk M, Workman P, Garrett MD, Collins I. Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2, 3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. J Med Chem. 2008;51(51):2147-57. (Pubitemid 351503270)
9. Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets. 2007;6(6):27-39.
10. Chung CW. The use of biophysical methods increases success in obtaining liganded crystal structures. Acta Crystallogr D Biol Crystallogr. 2007;63(Pt 1):62-71.
11. Ciulli A, Williams G, Smith AG, Blundell TL, Abell C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J Med Chem. 2006;49(49):4992-5000. (Pubitemid 44201057)
12. Ciulli A, Scott DE, Ando M, Reyes F, Saldanha SA, Tuck KL, Chirgadze DY, Blundell TL, and Abell C. Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. ChemBioChem. 2008;9(9):2606-2611.
13. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(393):537-44. (Pubitemid 28319235)
14. Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery? Drug Discov Today. 2003;8(8):876-7. (Pubitemid 37194496)
15. Congreve M, Murray CW, Blundell TL. Structural biology and drug discovery. Drug Discov Today. 2005;10(10):895-907.
16. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR. 2001;21(21):349-59. (Pubitemid 34071389)
17. Dias MV, Faím LM, Vasconcelos IB, de Oliveira JS, Basso LA, Santos DS, de Azevedo WF Jr. Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63(Pt 1):1-6. (Pubitemid 46067232)
18. Dover LG, Cerdeño-Tárraga AM, Pallen MJ, Parkhill J, Besra GS. Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae. FEMS Microbiol Rev. 2004;28(28):225-50. (Pubitemid 38510503)
19. Dubnau E, Chan J, Raynaud C, Mohan VP, Lanéelle MA, Yu K, Quémard A, Smith I, Daffé M. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol. 2000;36(36):630-7. (Pubitemid 30258847)
20. Garbe T, Servos S, Hawkins A, Dimitriadis G, Young D, Dougan G, Charles I. The Mycobacterium tuberculosis shikimate pathway genes: evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases. Mol Gen Genet. 1991;228(228):385-92.
21. George KM, Yuan Y, Sherman DR, Barry CE 3rd. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J Biol Chem. 1995;270(270):27292-8. (Pubitemid 3007299)
22. González-Bello C, Castedo L. Progress in type II dehydroquinase inhibitors: from concept to practice. Med Res Rev. 2007;27(27):177-208. (Pubitemid 46281146)
23. Gould TA, van de Langemheen H, Muñoz-Elías EJ, McKinney JD, Sacchettini JC. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis. Mol Microbiol. 2006;61(61):940-7. (Pubitemid 44134171)
24. Gourley DG, Shrive AK, Polikarpov I, Krell T, Coggins JR, Hawkins AR, Isaacs NW, Sawyer L. The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction. Nat Struct Biol. 1999;6(6):521-5. (Pubitemid 29252828)
25. Guerin ME, Kordulakova J, Schaeffer F, Svetlikova Z, Buschiazzo A, Giganti D, Gicquel B, Mikusova K, Jackson M, Alzari PM. Molecular recognition and interfacial catalysis by the essential phosphatidylinositol mannosyltransferase PimA from mycobacteria. J Biol Chem. 2007;282(282):20705-14. (Pubitemid 47100006)
26. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 2007;6(6):211-9. (Pubitemid 46344625)
27. Hartmann MD, Bourenkov GP, Oberschall A, Strizhov N, Bartunik HD. Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis. J Mol Biol. 2006;364(364):411-23. (Pubitemid 44780995)
28. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. J Med Chem. 2005;48(48):403-13. (Pubitemid 40139783)
29. Holdgate GA, Ward WH. Measurements of binding thermodynamics in drug discovery. Drug Discov Today. 2005;10(10):1543-50. (Pubitemid 41527197)
30. Holton SJ, Weiss MS, Tucker PA, Wilmanns M. Structure-based approaches to drug discovery against tuberculosis. Curr Protein Pept Sci. 2007;8(8):365-75. (Pubitemid 47317042)
31. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 2004;9(9):430-1. (Pubitemid 38510559)
32. Howard N, Abell C, Blakemore W, Chessari G, Congreve M, Howard S, Jhoti H, Murray CW, Seavers LC, van Montfort RL. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J Med Chem. 2006;49(49):1346-55. (Pubitemid 43271886)
33. Huang CC, Smith CV, Glickman MS, Jacobs WR Jr, Sacchettini JC. Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J Biol Chem. 2002;277(277):11559-69. (Pubitemid 34952927)
34. Jones G, Willet P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol. 1995;245(245):43-53.
35. Jones G, Willet P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(267):727-48. (Pubitemid 27170693)
36. Kairys V, Fernandes MX, Gilson MK. Screening drug-like compounds by docking to homology models: a systematic study. J Chem Inf Model. 2006;46(46):365-79. (Pubitemid 43282128)
37. Korduláková J, Gilleron M, Puzo G, Brennan PJ, Gicquel B, Mikusová K, Jackson M. Identification of the required acyltransferase step in the biosynthesis of the phosphatidylinositol mannosides of mycobacterium species. J Biol Chem. 2003;278(278):36285-95. (Pubitemid 37139953)
38. Lepre CA, Moore JM, Peng JW. Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev. 2004;104(104):3641-76.
39. Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL, Horng JT, Hsiao M, Tsou AP. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008; in press.
40. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3): 3-26. (Pubitemid 33653411)
41. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem. 2004;332(332):153-9. (Pubitemid 39099482)
42. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 2001;123(123):6108-17. (Pubitemid 32888480)
43. McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, Russell DG. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406(406):735-8.
44. Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology. 2002;148(Pt 10):3069-77. (Pubitemid 35243706)
45. Radestock S, Weil T, Renner S. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. J Chem Inf Model. 2008;48(48):1104-17.
46. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med. 2002;8(8):1171-4. (Pubitemid 35175974)
47. Sharma V, Sharma S, Hoener zu Bentrup K, McKinney JD, Russell DG, Jacobs WR Jr, Sacchettini JC. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol. 2000;7(7):663-8. (Pubitemid 30636678)
48. Silveira NJ, Bonalumi CE, Uchõa HB, Pereira JH, Canduri F, de Azevedo WF. DBMODELING: a database applied to the study of protein targets from genome projects. Cell Biochem Biophys. 2006;44(44):366-74. (Pubitemid 43780392)
49. Silveira NJ, Uchôa HB, Pereira JH, Canduri F, Basso LA, Palma MS, Santos DS, de Azevedo WF Jr. Molecular models of protein targets from Mycobacterium tuberculosis. J Mol Model. 2005;11(11):160-6.
50. Searls DB. Pharmacophylogenomics: genes, evolution and drug targets. Nat Rev Drug Discov. 2003;2(2):613-23. (Pubitemid 37361765)
51. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, Höner zu Bentrup K. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem. 2003;17; 278 (278):1735-43. (Pubitemid 36801408)
52. Sorensen TL, McAuley KE, Flaig R, Duke EM. New light for science: synchrotron radiation in structural medicine. Trends Biotechnol. 2006;24(24):500-8. (Pubitemid 44537458)
53. Tonge PJ, Kisker C, Slayden RA. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Curr Top Med Chem. 2007;7(7):489-98. (Pubitemid 46488289)
54. Toscano MD, Payne RJ, Chiba A, Kerbarh O, Abell C. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism. ChemMedChem. 2007;2(2):101-12.
55. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003;3(3):578-90. (Pubitemid 37064537)
56. Velaparthi S, Brunsteiner M, Uddin R, Wan B, Franzblau SG, Petukhov PA. 5-tert-Butyl-N-pyrazol-4-yl-4, 5, 6, 7-tetrahydrobenzo[d]isoxazole-3-carboxamide Derivatives as Novel Potent Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase: Initiating a Quest for New Antitubercular Drugs. J Med Chem. 2008;51(51):1999-2002. (Pubitemid 351503254)
57. von Delft F, Lewendon A, Dhanaraj V, Blundell TL, Abell C, Smith AG. The crystal structure of E. coli pantothenate synthetase confirms it as a member of the cytidylyltransferase superfamily. Structure. 2001;9(9):439-50. (Pubitemid 32497271)
58. Wang S, Eisenberg D. Crystal structure of the pantothenate synthetase from Mycobacterium tuberculosis, snapshots of the enzyme in action. Biochemistry. 2006;45(45):1554-61. (Pubitemid 43222099)
59. White EL, Southworth K, Ross L, Cooley S, Gill RB, Sosa MI, Manouvakhova A, Rasmussen L, Goulding C, Eisenberg D, Fletcher TM 3rd. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen. 2007;12(12):100-5. (Pubitemid 46224924)
60. WHO Report 2008, Global tuberculosis control-surveillance, planning, financing, WHO/HTM/TB/2008.393
61. Worth CL, Bickerton GR, Schreyer A, Forman JR, Cheng TM, Lee S, Gong S, Burke DF, Blundell TL. A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease., J Bioinform Comput Biol. 2007;5(5):1297-318.